- Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
On Friday, Cyclacel Pharmaceuticals Inc (CYCC:NAQ) closed at 1.61, 23.85% above the 52 week low of 1.30 set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.62 |
---|---|
High | 1.66 |
Low | 1.60 |
Bid | 1.60 |
Offer | 1.66 |
Previous close | 1.63 |
Average volume | 162.37k |
---|---|
Shares outstanding | 1.46m |
Free float | 1.36m |
P/E (TTM) | -- |
Market cap | 2.36m USD |
EPS (TTM) | -21.99 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:59 BST.
More ▼